Rapidly Progressive Visual Field Deterioration in a Glaucomatous Patient Treated with Several Anti-VEGF Injections for Neovascular AMD: A Case Report

Coraline Calci; Daniela Gallo Castro; Yannic Pannatier Schuetz; André Mermoud; Aude Ambresin

doi:10.1055/a-2004-5664

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2023; 240(04): 478-480
DOI: 10.1055/a-2004-5664

Der interessante Fall

Rapidly Progressive Visual Field Deterioration in a Glaucomatous Patient Treated with Several Anti-VEGF Injections for Neovascular AMD: A Case Report

Rasch fortschreitende Gesichtsfeldverschlechterung bei einem Glaukompatienten, der mit mehreren Anti-VEGF-Injektionen gegen neovaskuläre AMD behandelt wurde: ein Fallbericht

Authors

Coraline Calci

¹Ophthalmology, Swiss Visio Montchoisi – Centre B Lausanne, CH, Lausanne, Switzerland
Daniela Gallo Castro

²Ophthalmology, Swiss Visio Retina Research, Center, Lausanne, Switzerland
Yannic Pannatier Schuetz

²Ophthalmology, Swiss Visio Retina Research, Center, Lausanne, Switzerland
André Mermoud

¹Ophthalmology, Swiss Visio Montchoisi – Centre B Lausanne, CH, Lausanne, Switzerland

³Ophthalmology, Swiss Glaucoma Research Fondation, Lausanne, Switzerland
Aude Ambresin

¹Ophthalmology, Swiss Visio Montchoisi – Centre B Lausanne, CH, Lausanne, Switzerland

²Ophthalmology, Swiss Visio Retina Research, Center, Lausanne, Switzerland

Abstract

Full Text

References

References
1 Heier JS, Brown DM, Chong V. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548
2 Rosenfeld PJ, Brown DM, Heier JS. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
3 Brown DM, Kaiser PK, Michels M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444
4 Kim JE, Mantravadi AV, Hur EY. et al. Short-term Intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008; 146: 930-934.e1
5 Hollands H, Wong J, Bruen R. et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42: 807-811
6 Mojica G, Hariprasad SM, Jager RD. et al. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol 2008; 92: 584-584
7 Horsley MB, Mandava N, Maycotte MA. et al. Retinal nerve fiber layer thickness in patients receiving chronic anti–vascular endothelial growth factor therapy. Am J Ophthalmol 2010; 150: 558-561.e1
8 Beck M, Munk MR, Ebneter A. et al. Retinal Ganglion Cell Layer Change in Patients Treated With Anti–Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration. Am J Ophthalmol 2016; 167: 10-17
9 Khaw PT. Glaucoma–1: diagnosis. BMJ 2004; 328: 97-99
10 Wen JC, Chen CL, Rezaei KA. et al. Optic Nerve Head Perfusion Before and After Intravitreal Antivascular Growth Factor Injections Using Optical Coherence Tomography-based Microangiography. J Glaucoma 2019; 28: 188-193
11 Riva CE, Hero M, Titze P. et al. Autoregulation of human optic nerve head blood flow in response to acute changes in ocular perfusion pressure. Graefes Arch Clin Exp Ophthalmol 1997; 235: 618-626
12 Tsui JL, Lau IH, Li SL. et al. Predictors of elevated intraocular pressure after intravitreal injection of anti-vascular endothelial growth factor: a prospective observational study. Hong Kong J Ophthalmol 2021; 25: 6-11
13 Hoguet A, Chen PP, Junk AK. et al. The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma. Ophthalmology 2019; 126: 611-622
14 Agard E, Elchehab H, Ract-Madoux G. et al. Repeated intravitreal anti–vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can J Ophthalmol 2015; 50: 127-131
15 Poli M, Denis P, Dot C. et al. Conduite à tenir face au risque dʼhypertonie oculaire après injection intra-vitréenne. J Fr Ophtalmol 2017; 40: e77-e82